The objective of the Institute of Translational Stem Cell Research (ITS) is to develop a stem cell-based replacement therapy in type 1 diabetes. The scientists aim to develop safe approaches for up-scaled production of insulin-producing beta cells from human pluripotent stem cells (hPSCs). An important milestone in the short term is the proper production of the cells following defined standards of Good Manufacturing Practice (GMP). The ITS works closely together with the University of Copenhagen. More information